Laser or cream? new study tackles vaginal dryness in Sjögren's
NCT ID NCT07153276
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests two treatments for vaginal dryness in women with Sjögren's disease: a fractional CO2 laser applied monthly for three months, and a topical promestriene cream used for six months. Sixty participants will be randomly assigned to one of the two groups. The goal is to see which treatment better improves vaginal health and sexual function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Fractional CO2 laser (vaginal) and promestriene vaginal capsules
- What this could lead to
- If successful, this could provide effective, non-hormonal or hormonal treatment options for vaginal dryness in Sjögren's disease, improving quality of life and sexual health.
- What could go wrong
- This is a small, early-phase study (60 participants) comparing two treatments, so results may not apply to all patients. Both treatments have known risks like discomfort or irritation, and the laser is not yet proven for this condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SJOGREN SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Sao Paulo General Hospital
RECRUITINGSão Paulo, São Paulo, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New eye drops aim to calm Sjögren's dry eye by blocking inflammation
- Scientists investigate immune cell role in rare IgG4 disease
- New hope for Sjögren's fatigue: acupuncture and nerve zaps join exercise in clinical trial
- Rare disease pregnancy study pulled before it began
- New Sjögren's drug shows promise in small study
- Blood test may predict dangerous immunotherapy reactions